v3.24.0.1
Consolidated Balance Sheets - USD ($)
$ in Thousands
Dec. 31, 2023
Dec. 31, 2022
Current assets:    
Cash and cash equivalents $ 22,544 $ 9,981
Available-for-sale investments 75,622 56,165
Other receivables 2,436 11,775
Prepaid expenses 2,390 2,950
Total current assets 102,992 80,871
Restricted cash 3,484 3,165
Property and equipment, net 5,531 3,059
Operating lease, right-of-use assets 6,727 7,250
Financing lease, right-of-use assets 1,788 1,248
Other assets 131 193
Total assets 120,653 95,786
Current liabilities:    
Accounts payable 3,529 3,106
Accrued expenses 11,559 9,862
Current portion of operating lease liability 831 630
Current portion of financing lease liability 497 264
Total current liabilities 16,416 13,862
Long-term operating lease liability, net of current portion 12,339 9,633
Long-term financing lease liability, net of current portion 1,428 1,007
Commitments and contingencies (Note 6)
Stockholders’ equity:    
Preferred stock, $0.001 par value per share; 5,000,000 undesignated authorized shares as of December 31, 2023 and 2022, respectively; no shares issued or outstanding as of December 31, 2023 and 2022, respectively
Common stock, $0.001 par value per share; 170,000,000 and 85,000,000 authorized shares as of December 31, 2023 and 2022, respectively; issued and outstanding shares - 63,286,404 and 29,498,488 as of December 31, 2023 and 2022, respectively 63 29
Additional paid-in capital 558,692 489,502
Accumulated other comprehensive loss (74) (433)
Accumulated deficit (468,023) (417,634)
Total aTyr Pharma stockholders’ equity 90,658 71,464
Noncontrolling interest in Pangu BioPharma Limited (188) (180)
Total stockholders' equity 90,470 71,284
Total liabilities and stockholders’ equity $ 120,653 $ 95,786